Results: Plasma CCL5 was causally associated with breast cancer in the MR analysis, which was significant in the luminal and HER-2 enriched subtypes and further confirmed using PRS analysis (OR = 0.94 ...

This study is important, and the findings add substantially to the evidence base regarding CCR5 antagonist drugs for neuroprotection and stroke management. The authors adhered to the expected ...

Summary: Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of CCR5-tropic human immunodeficiency virus ...

These sites bind to coreceptor CCR5 or CXCR4 on the membrane of the host cell (center panel), an event that initiates steps that culminate in the fusion of the HIV envelope with the host cell ...

Engineered EVA-P974(F31A) inhibits receptor activation by multiple chemokines. Combined activation of CCR1 and CCR2 in THP-1 monocytes by the chemokine mixture CCL2+CCL5+CCL7 (orange) is fully ...

The cytokine CCL5 is elevated following Her2 downregulation and remains high in residual tumors. CCL5 promotes tumor recurrence by recruiting CCR5-expressing macrophages, which may contribute to ...

Objective: Characterization of altered expression of selected transcripts linked to inflammation in the peripheral blood of sporadic amyotrophic lateral sclerosis (sALS) patients at early stage of ...